Why the study?
The study aimed to evaluate ARVC/D in affected families with desmosome mutations using the recently revised Task Force Criteria.
Does the revised Task Force Criteria improve diagnostic sensitivity and specificity for ARVC/D in families with desmosomal mutations compared to the original criteria?
Does the revised Task Force Criteria improve diagnostic sensitivity and specificity for ARVC/D in families with desmosomal mutations compared to the original criteria?
The revised Task Force Criteria significantly improved diagnostic sensitivity and specificity for ARVC/D in families with desmosomal mutations, with electrocardiography showing the best diagnostic utility in early disease.
Answers are grounded in this paper and cite their sources.
May improve ARVC detection in dominant desmosomal families; leaves open prognostic value and requires prospective validation.
AIMS: To evaluate arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in affected families with desmosome mutations on the basis of the recently revised Task Force Criteria (TFC). METHODS AND RESULTS: One hundred and three consecutive carriers of pathogenic desmosome mutations and 102 mutation-negative relatives belonging to 22 families with dominant and 14 families with recessive ARVC/D were evaluated according to the original and revised TFC. Serial cardiac assessment with 12-lead, signal-averaged, and 24 h ambulatory ECG and two-dimensional echocardiography was performed. Clinical events and outcome were prospectively analysed up to 24 years (median 4 years). With the revised criteria, 16 carriers were newly diagnosed on the basis of ECG abnormalities in 100%, ventricular arrhythmias in 79%, and functional/structural alterations in 31%, increasing diagnostic sensitivity from 57 to 71% (P = 0.001). Task Force Criteria specificity improved from 92 to 99% (P = 0.016). In dominant mutation carriers, penetrance changed significantly (61 vs. 42%, P = 0.001); no changes were observed in recessive homozygous carriers (97 vs. 97%, P = 1.00). Affected carriers according to the revised TFC (n = 73) had 12-lead ECG abnormalities in 96%, ventricular arrhythmias in 91%, and functional/structural alterations fulfilling echocardiographic criteria in 76%. Cumulative and event-free survival did not differ significantly between dominant and recessive affected carriers, being at 78.6 vs. 76 and 51.7 vs. 55.4%, respectively, by the age of 40 years. CONCLUSION: Revised TFC increased diagnostic sensitivity particularly in dominant ARVC/D. Serial family evaluation may rely on electrocardiography which seems to have the best diagnostic utility particularly in early disease that is not detectable by two-dimensional echocardiography.
No takes yet. Share an insight, caveat, or question.
Protonotarios et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: